ArticleMicrobial cell factories2021
Bacillus subtilis revives conventional antibiotics against Staphylococcus aureus osteomyelitis.
Article in Microbial cell factories, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Bioprinted core-shell living material platform for spatially controlled encapsulation ofBioactive materials · 2027Article
- Osteomyelitis: Epidemiology, Classification, Pathophysiology, Clinical Features, Diagnosis, and Management.MedComm · 2026Review
- Click-crosslinked nano-hydrogel enables metabolic immune reprogramming for diabetic foot ulcers.Science China. Life sciences · 2026Article
- Antibiofilm, Antimicrobial, and Limited Ammonia-Reduction Activities of Bacillus cereus-Group Isolates From Hot Spring Sediment and Rubber Latex Serum for Aquaculture Water Management.Water environment research : a research publication of the Water Environment Federation · 2026Article
- Probiotic characterization of Lactobacillus helveticus BGTRM7-58 from Khiki cheese: safety, antimicrobial activity, antioxidant capacity, and anti-biofilm effects against Staphylococcus aureus.BMC microbiology · 2026Article
- Microbiome-Targeted Probiotic Strategies for the Prevention and Treatment of Osteomyelitis: A Novel Biological Approach.Probiotics and antimicrobial proteins · 2026Review
- Article
- Article
- Anti-Biofilm Properties of Cell-Free Supernatant fromMicroorganisms · 2025Article
- Article
- Article
- Screening of different growth conditions ofOpen life sciences · 2024Article
- The overlooked bacterial pandemic.Seminars in immunopathology · 2024Review
- Probiotics and Their Bioproducts: A Promising Approach for Targeting Methicillin-ResistantMicroorganisms · 2023Review
- Interspecies interaction reduces selection for antibiotic resistance in Escherichia coli.Communications biology · 2023Article
- Antibiotic Resistance Crisis: An Update on Antagonistic Interactions between Probiotics and Methicillin-Resistant Staphylococcus aureus (MRSA).Current microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
As treatment of Staphylococcus aureus (S. aureus) osteomyelitis is often hindered by the development of antibiotic tolerance, novel antibacterial therapeutics are required. Here we found that the cell-free supernatant of Bacillus subtilis (B. subtilis CFS) killed planktonic and biofilm S. aureus, and increased S. aureus susceptibility to penicillin and gentamicin as well. Further study showed that B. subtilis CFS suppressed the expression of the genes involved in adhesive molecules (Cna and ClfA), virulence factor Hla, quorum sensing (argA, argB and RNAIII) and biofilm formation (Ica and sarA) in S. aureus. Additionally, our data showed that B. subtilis CFS changed the membrane components and increased membrane permeabilization of S. aureus. Finally, we demonstrated that B. subtilis CFS increased considerably the susceptibility of S. aureus to penicillin and effectively reduced S. aureus burdens in a mouse model of implant-associated osteomyelitis. These findings support that B. subtilis CFS may be a potential resistance-modifying agent for β-lactam antibiotics against S. aureus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.